Selected Publications

Patel, H., Hubbeling, H., Yu, K., Carpenter, M., LaRiviere, M., Cohen, A., Kapur, S., Vogl, D., Waxman, A., Stadtmauer, E. and Garfall, A.: Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. Elsevier, 25: 99, Sep 2025.

Cohen, A., Susanibar-Adaniya, S., Garfall, A., Vogl, D., Kapur, S., Waxman, A., Zubka, D., Hwang, W.T., Diaczynsky, C., Noll, J. and Ho, M.: Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM”(Sequential T Cell-Engagement for Myeloma) Trial. Clinical Lymphoma Myeloma and Leukemia. Elsevier, 25: 366, Sep 2025.

Yu, K., Ho, M., Paruzzo, L., Patel, H., Ruella, M., Kapur, S., Waxman, A., Vogl, D., Cohen, A., Stadtmauer, E. and Garfall, A.: Clinical Outcomes after Teclistamab Failure in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 25, pp.S64-S65. Elsevier, 25: 64-65, Sep 2025.

Matthew Ho, Luca Paruzzo, Julia Noll, Federico Stella, Sonia Ndeupen, Pooja Devi, Adam Waxman, Shivani Kapur, Fang Chen, Rong Xu, Andrew Huff, Peter Michener, Vanessa Gonzalez, Dan Vogl, David Porter, Aoife Roche, John Everett, Frederic Bushman, Katherine Nathanson, Edward Stadtmauer, Sandra Susanibar-Adaniya, Alfred Garfall, Marco Ruella, Joseph Fraietta, Adam Cohen : CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy. Clinical Lymphoma Myeloma and Leukemia, 25, p.S3. Elsevier, 25(3), Sep 2025.

Paruzzo, L., Eshaghi, K., Ghilardi, G., Doucette, A., Ho, M., Carturan, A., Vogl, D.T., Waxman, A.J., Kapur, S., Fardella, E. and Pucillo, M.: Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma. Blood Immunology & Cellular Therapy. Elsevier, 1(2): 100007, Sep 2025.

Paruzzo, L., Luo, T., Ho, M., Patel, H., Stella, F., Vogl, D., Kapur, S., Waxman, A., Porazzi, P., Carturan, A. and Pucillo, M.: Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma—A Retrospective Evaluation. Clinical Lymphoma Myeloma and Leukemia. Elsevier, 25: 92-93. Sep 2025.

Luo, T., Paruzzo, L., Susanibar Adaniya, S.P., Garfall, A.L., Ho, M., Kapur, S., Ruella, M., Stadtmauer, E.A., Stella, F., Vogl, D.T. and Waxman, A.J.: Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. American Society of Clinical Oncology, 43: 7518, Jun 2025.

Vogl, D.T., Nefedova, Y., Wileyto, E.P., Whittington, S., Diaczynsky, C., Nguyen, C.T., Strakovsky, I., Bondesson, E., Tuvesson, H., Vahtola, E. and Cohen, A.D.: Clinical Activity of Novel Targeting of S100A9 with Tasquinimod for Relapsed and Refractory Multiple Myeloma (RRMM). Journal of Clinical Oncology American Society of Clinical Oncology, 43: 7555, Jun 2025.

Ho, M., Paruzzo, L., Minehart, J., Voruganti, T., Devi, P., Vogl, D.T., Cohen, A.D., Garfall, A.L., Waxman, A.J., Kapur, S. and Stadtmauer, E.A.: Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica. Ferrata-Storti Foundation, 110(6): 1436-1442, Feb 2025.

Elghawy, O., Deshpande, S., Sussman, J., Garfall, A., Cohen, A., Kapur, S., Susanibar-Adaniya, S., Vogl, D., Waxman, A. and Stadtmauer, E.: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Nature: Bone Marrow Transplantation. Nature Publishing Group UK 60(1): 64-68, Jan 2025.